O-GlcNAcylation is a mitochondrial-nuclear signal that regulates passive transport through the nuclear pore complex
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Talia Hart und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School,…. Hauptthemen laut MEDLINE: Mitochondria, Nuclear Pore, N-Acetylglucosaminyltransferases, Cell Nucleus. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
The nuclear pore complex (NPC) is the single gateway between the nucleus and the cytoplasm, and in healthy cells there is a size threshold for passive diffusion across the NPC. In aging and disease, the NPC deteriorates, leading to promiscuous passive transport. We have previously showed that NPC protein expression is required for biguanide-induced lifespan extension, mTOR inhibition, and further that biguanide treatment leads to restriction of passive nuclear transport, but the underlying changes leading to this restriction were not identified. Here, we use fluorescent dextran transport and biochemical assays in HeLa cells to clarify the mechanism by which biguanide phenformin alters NPC permeability. We find phenformin treatment in HeLa cells leads to restricted passive nuclear transport in a dose and time-dependent manner. Multiple inhibitors of the mitochondrial electron transport chain also restrict passive nucleocytoplasmic transport. Critically, phenformin reduced expression of O-linked N-acetylglucosamine (O-GlcNAc) transferase, lowering global O-GlcNAcylation and locally decreasing O-GlcNAcylation of Nup98. O-GlcNAc transferase inhibition alone restricts passive transport, while increasing O-GlcNAcylation reverses phenformin's effects. These results identify O-GlcNAc as a mitochondrial-nuclear signal and show that electron transport chain inhibition rapidly modulates nucleocytoplasmic transport via NPC post-translational modification in human cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Broad Institute of Harvard and MIT, Cambr…
- Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ayerevanian@mgh.harva…
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Hart, T., Duke, A., Zhou, Y., Soukas, A. A., & Yerevanian, A. I. (2026). O-GlcNAcylation is a mitochondrial-nuclear signal that regulates passive transport through the nuclear pore complex. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113343
Vancouver
Hart T, Duke A, Zhou Y, Soukas AA, Yerevanian AI. O-GlcNAcylation is a mitochondrial-nuclear signal that regulates passive transport through the nuclear pore complex. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113343
BibTeX
@article{Hart2026,
author = {Hart, Talia and Duke, Ashley and Zhou, Yifei and Soukas, Alexander A and Yerevanian, Armen I},
title = {O-GlcNAcylation is a mitochondrial-nuclear signal that regulates passive transport through the nuclear pore complex},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113343}
}
EUVIMED